Zensar Technologies Limited (ZENSARTECH)
In-principle approval for Merger of the US-based step-down subsidiary(ies) of the Company
In-principle approval granted for merger of US-based step-down subsidiaries Bridgeview Life Sciences LLC and M3BI LLC into Zensar Technologies Inc., USA.
- Bridgeview Life Sciences LLC net worth USD 0.4M, turnover USD 4.74M FY26
- M3BI LLC net worth USD 9.32M, turnover USD 46.8M FY26
- Zensar Technologies Inc. net worth USD 74.66M, turnover USD 326.96M FY26
- Merger aims for business synergies and operational efficiencies
- No cash consideration or shareholding pattern change involved
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ZENSARTECH — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ZENSARTECH to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Zensar Technologies Limited
Important.
The summary above is generated automatically from Zensar Technologies Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.